MET and non-small cell lung carcinoma: In a second cohort of 40 patients, englobing 18 primary NSCLC from patients who later developed brain metastases and 22 NSCLC from patients that did not develop brain metastases, Benedettini et al. demonstrated that both C-MET expression and phosphorylation, but not C-MET amplification, were significantly higher in the tumors from patients who developed brain metastasis.